The Association for Clinical Oncology (ASCO) is carefully reviewing the Administration’s Fiscal Year 2026 “skinny” budget proposal, which was released May 2 and contains significant cuts to federal ...

The Association for Clinical Oncology (ASCO) would like to hear from members of the cancer care community who are experiencing an impact from supply chain issues. These effects could include shortages ...

Open comment allows key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication. It allows for greater transparency in the ASCO ...

ASCO is urging lawmakers to ensure America continues to lead in research through continued bipartisan support for federal health agencies and the scientists driving daily progress. Ahead of the April ...

For reference, please review the following policies and guidelines. As you prepare your submission to the Meeting, please make note of the following author and sponsorship eligibility criteria: ...

The deadline for early registration and hotel reservations is April 23, 2025, at 11:59 PM ET. Below you will find registration rates and details, hotel information, and links to book your hotel and ...

CMS proposes a 2.4% increase in operating payment rates for general acute care hospitals paid under IPPS that successfully participate in the Hospital Inpatient Quality Reporting (IQR) program and are ...

Members of the Association for Clinical Oncology (ASCO) were on Capitol Hill on April 8, 2025, for the 10th annual ASCO Advocacy Summit, where they met with lawmakers to discuss critical issues in ...

SPARGO, Inc. is the only official registration and housing provider for ASCO Meetings and Symposia. Individuals unaffiliated with ASCO or SPARGO, Inc. may entice prospective attendees into registering ...

The U.S. Supreme Court issued an opinion on Wednesday, April 2, that the Food and Drug Administration (FDA) was within its power to regulate the sale of certain flavored e-cigarette products. The case ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers ...